DIVESTITURES |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Discontinued Operations and Disposal Groups [Abstract] | |
| DIVESTITURES | DIVESTITURES Discontinued Operations Sale of Bile Acid Product Portfolio In August 2023, the Company closed the sale of its bile acid business to Mirum Pharmaceuticals, Inc. (“Mirum”) pursuant to the terms of an asset purchase agreement dated July 16, 2023 (the "Purchase Agreement"). The Company is eligible to receive up to $235.0 million upon the achievement of certain milestones based on specified amounts of annual net sales (tiered from $125.0 million to $500.0 million) of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the "Products"). The Company will recognize the contingent consideration receivable in earnings when the target annual sales for the milestones are met and the contingency is resolved. Mirum achieved the first such milestone based on its annual net sales in 2025, and Travere recognized a milestone of $25.0 million for the year ended December 31, 2025 in discontinued operations. The $25.0 million is included in accounts receivable as of December 31, 2025 and payment was received in April 2026. Loss from discontinued operations for the three and six months ended June 30, 2026 was zero and $0.5 million, respectively and zero for both the three and six months ended June 30, 2025.
|